Kamada .(US:KMDA) Benzinga·2025-12-08 16:05Core Viewpoint - Kamada Ltd. has decided to discontinue its Phase 3 InnovAATe trial for Inhaled AAT aimed at treating Alpha-1 Antitrypsin Deficiency (AATD) due to low likelihood of demonstrating a statistically significant benefit in lung function [1][3]. Company Updates - The discontinuation of the trial follows advice from an independent Data and Safety Monitoring Board (DSMB) based on a prespecified interim futility analysis [3]. - CEO Amir London expressed disappointment over the trial's outcome but emphasized the company's strong position for future growth prospects [4]. - Kamada reiterated its full-year 2025 revenue guidance of $178 million to $182 million, aligning closely with the consensus of $180.66 million, and provided adjusted EBITDA guidance of $40 million to $44 million [5]. Future Outlook - The company projects double-digit growth in revenues and profitability for 2026, supported by its commercial portfolio, which includes six FDA-approved specialty plasma-derived products marketed in over 30 countries [6]. - Kamada is also focusing on expanding its biosimilar portfolio in Israel and increasing plasma collection capacity, while pursuing new business development opportunities to ensure long-term growth [6]. Market Reaction - Following the announcement, Kamada's stock experienced a decline of 5.51%, trading at $6.69 [7].